Biocryst Pharmaceuticals (BCRX) Is Today's Perilous Reversal Stock
- BCRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $16.4 million.
- BCRX has traded 240,810 shares today.
- BCRX is down 5.3% today.
- BCRX was up 8.6% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in BCRX with the Ticky from Trade-Ideas. See the FREE profile for BCRX NOW at Trade-Ideas More details on BCRX: BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. Currently there are 3 analysts that rate Biocryst Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold. The average volume for Biocryst Pharmaceuticals has been 951,200 shares per day over the past 30 days. Biocryst has a market cap of $595.6 million and is part of the health care sector and drugs industry. The stock has a beta of 3.34 and a short float of 17.5% with 5.22 days to cover. Shares are up 32.6% year-to-date as of the close of trading on Monday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Biocryst Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally high debt management risk. Highlights from the ratings report include:
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, BIOCRYST PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- The debt-to-equity ratio is very high at 8.80 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Despite the company's weak debt-to-equity ratio, the company has managed to keep a very strong quick ratio of 3.42, which shows the ability to cover short-term cash needs.
- BCRX, with its very weak revenue results, has greatly underperformed against the industry average of 10.6%. Since the same quarter one year prior, revenues plummeted by 58.5%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
- This stock has increased by 514.90% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the future course of this stock, we feel that the risks involved in investing in BCRX do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
- BIOCRYST PHARMACEUTICALS INC has improved earnings per share by 26.3% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, BIOCRYST PHARMACEUTICALS INC continued to lose money by earning -$0.79 versus -$1.26 in the prior year. This year, the market expects an improvement in earnings (-$0.53 versus -$0.79).
- You can view the full Biocryst Pharmaceuticals Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.